Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
October 21 2021 - 8:30AM
Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a
clinical stage biopharmaceutical company seeking to discover and
develop innovative medicines in areas of significant unmet medical
need in oncology and infectious diseases with a current focus on
breast cancer and COVID-19, today released a short video message
recognizing Breast Cancer Awareness Month, and urging women to get
mammograms.
In the video message, which can be found on
Atossa’s website here, Dr. Quay cites that the global pandemic
“changed everything” with regard to breast cancer screening,
indicating that many women have ceased to seek out their mammograms
since the initial COVID-19 outbreak. This is corroborated in an
article in the October 2021 issue of the peer-reviewed medical
journal, Preventative Medicine, which indicated this was a
particular problem in women of color and those who fall in the
lower income brackets.
ABOUT ATOSSA THERAPEUTICS
Atossa Therapeutics, Inc. is a clinical-stage
biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need in
oncology and infectious diseases with a current focus on breast
cancer and COVID-19. For more information, please
visit www.atossatherapeutics.com.
FORWARD-LOOKING STATEMENTS DISCLAIMER
STATEMENT
Forward-looking statements in this press release,
which Atossa undertakes no obligation to update, are subject to
risks and uncertainties that may cause actual results to differ
materially from the anticipated or estimated future results,
including, without limitation, statements regarding the
satisfaction of closing conditions relating to the offering and the
anticipated use of proceeds from the offering, the risks and
uncertainties associated with any variation between interim and
final clinical results, actions and inactions by the FDA, the
outcome or timing of regulatory approvals needed by Atossa
including those needed to commence and continue studies of AT-H201,
AT-301 and Endoxifen, lower than anticipated rate of patient
enrollment, estimated market size of drugs under development, the
safety and efficacy of Atossa’s products, performance of clinical
research organizations and investigators, obstacles resulting from
proprietary rights held by others such as patent rights, whether
reduction in Ki-67 or any other result from a neoadjuvant study or
reduction of breast density will be approvable endpoints for oral
Endoxifen, and other risks detailed from time to time in Atossa’s
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
COMPANY CONTACT:
Atossa Therapeutics, Inc.Kyle Guse, CFO and General
CounselOffice: (866)
893-4927kyle.guse@atossainc.com
INVESTOR RELATIONS CONTACT:Core
IROffice: (516) 222-2560ir@atossainc.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2024 to May 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From May 2023 to May 2024